RU2015110027A - Композиции, включающие единичный вариабельный домен и камостат мезилат (см) - Google Patents
Композиции, включающие единичный вариабельный домен и камостат мезилат (см) Download PDFInfo
- Publication number
- RU2015110027A RU2015110027A RU2015110027A RU2015110027A RU2015110027A RU 2015110027 A RU2015110027 A RU 2015110027A RU 2015110027 A RU2015110027 A RU 2015110027A RU 2015110027 A RU2015110027 A RU 2015110027A RU 2015110027 A RU2015110027 A RU 2015110027A
- Authority
- RU
- Russia
- Prior art keywords
- composition
- variable domain
- single variable
- disease
- gastrointestinal tract
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract 33
- XASIMHXSUQUHLV-UHFFFAOYSA-N camostat Chemical compound C1=CC(CC(=O)OCC(=O)N(C)C)=CC=C1OC(=O)C1=CC=C(N=C(N)N)C=C1 XASIMHXSUQUHLV-UHFFFAOYSA-N 0.000 title claims abstract 7
- 229960000772 camostat Drugs 0.000 title claims abstract 7
- 210000001035 gastrointestinal tract Anatomy 0.000 claims abstract 10
- 239000003814 drug Substances 0.000 claims abstract 8
- 201000010099 disease Diseases 0.000 claims abstract 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 6
- 238000000034 method Methods 0.000 claims abstract 6
- 208000027496 Behcet disease Diseases 0.000 claims abstract 4
- 208000009137 Behcet syndrome Diseases 0.000 claims abstract 4
- 208000015943 Coeliac disease Diseases 0.000 claims abstract 4
- 206010009900 Colitis ulcerative Diseases 0.000 claims abstract 4
- 208000011231 Crohn disease Diseases 0.000 claims abstract 4
- 101000845170 Homo sapiens Thymic stromal lymphopoietin Proteins 0.000 claims abstract 4
- 102000003816 Interleukin-13 Human genes 0.000 claims abstract 4
- 108090000176 Interleukin-13 Proteins 0.000 claims abstract 4
- 102000003810 Interleukin-18 Human genes 0.000 claims abstract 4
- 108090000171 Interleukin-18 Proteins 0.000 claims abstract 4
- 102000013264 Interleukin-23 Human genes 0.000 claims abstract 4
- 108010065637 Interleukin-23 Proteins 0.000 claims abstract 4
- 108090001005 Interleukin-6 Proteins 0.000 claims abstract 4
- 102000017578 LAG3 Human genes 0.000 claims abstract 4
- 101150030213 Lag3 gene Proteins 0.000 claims abstract 4
- 206010028116 Mucosal inflammation Diseases 0.000 claims abstract 4
- 201000010927 Mucositis Diseases 0.000 claims abstract 4
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 claims abstract 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims abstract 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims abstract 4
- 201000006704 Ulcerative Colitis Diseases 0.000 claims abstract 4
- 206010009887 colitis Diseases 0.000 claims abstract 4
- 229940079593 drug Drugs 0.000 claims abstract 4
- 210000002200 mouth mucosa Anatomy 0.000 claims abstract 4
- 102000005962 receptors Human genes 0.000 claims abstract 4
- 108020003175 receptors Proteins 0.000 claims abstract 4
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims abstract 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims abstract 3
- 102000004889 Interleukin-6 Human genes 0.000 claims abstract 2
- 238000004519 manufacturing process Methods 0.000 claims abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 2
- 230000007704 transition Effects 0.000 claims abstract 2
- 108091005804 Peptidases Proteins 0.000 claims 4
- 239000004365 Protease Substances 0.000 claims 4
- 102000035195 Peptidases Human genes 0.000 claims 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 2
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 1
- 108090000317 Chymotrypsin Proteins 0.000 claims 1
- 108010019160 Pancreatin Proteins 0.000 claims 1
- 108090000631 Trypsin Proteins 0.000 claims 1
- 102000004142 Trypsin Human genes 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 229960002376 chymotrypsin Drugs 0.000 claims 1
- 239000002702 enteric coating Substances 0.000 claims 1
- 238000009505 enteric coating Methods 0.000 claims 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 229940055695 pancreatin Drugs 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 239000012588 trypsin Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/204—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261691443P | 2012-08-21 | 2012-08-21 | |
| US61/691,443 | 2012-08-21 | ||
| PCT/IB2013/001814 WO2014030049A2 (en) | 2012-08-21 | 2013-08-21 | Compositions comprising a single variable domain and camostat mesylate (cm) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2015110027A true RU2015110027A (ru) | 2016-10-10 |
Family
ID=49510445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015110027A RU2015110027A (ru) | 2012-08-21 | 2013-08-21 | Композиции, включающие единичный вариабельный домен и камостат мезилат (см) |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20150306058A1 (enExample) |
| EP (1) | EP2887960A2 (enExample) |
| JP (1) | JP2015527357A (enExample) |
| KR (1) | KR20150043342A (enExample) |
| CN (1) | CN104884089A (enExample) |
| AU (1) | AU2013304627A1 (enExample) |
| BR (1) | BR112015003851A2 (enExample) |
| CA (1) | CA2882684A1 (enExample) |
| IN (1) | IN2015DN01147A (enExample) |
| RU (1) | RU2015110027A (enExample) |
| WO (1) | WO2014030049A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3663B1 (ar) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
| BR112017010793A2 (pt) * | 2014-11-24 | 2017-12-26 | Regeneron Pharma | animal não humano geneticamente modificado, camundongo, métodos para produzir um animal não humano geneticamente modificado e de triagem de candidatos a fármaco direcionados a um antígeno de interesse, e, modelo de camundongo. |
| AU2016239949A1 (en) | 2015-03-31 | 2017-09-07 | Sorriso Pharmaceuticals, Inc. | Peptide construct having a protease-cleavable linker |
| WO2016156468A1 (en) | 2015-03-31 | 2016-10-06 | Vhsquared Limited | Polypeptides |
| ES2984656T3 (es) * | 2015-05-13 | 2024-10-30 | Ablynx Nv | Polipéptidos que reclutan linfocitos T en función de la reactividad a CD3 |
| IL300122A (en) | 2015-11-18 | 2023-03-01 | Merck Sharp ַ& Dohme Llc | Substances that bind to PD1 and/or LAG3 |
| BR112018012352A2 (pt) | 2015-12-16 | 2018-12-11 | Merck Sharp & Dohme Corp. | anticorpos anti-lag3 e fragmentos de ligação ao antígeno |
| EP3435982A1 (en) * | 2016-03-31 | 2019-02-06 | VHsquared Limited | Compositions |
| CA3144566A1 (en) | 2019-06-21 | 2020-12-24 | Sorriso Pharmaceuticals, Inc. | Polypeptides |
| US12570736B2 (en) | 2019-06-21 | 2026-03-10 | Sorriso Pharmaceuticals, Inc. | Compositions |
| JP7692844B2 (ja) | 2019-06-21 | 2025-06-16 | ソリッソ ファーマシューティカルズ，インク． | ポリペプチド |
| CA3171958A1 (en) * | 2020-03-18 | 2021-09-23 | Memorial Sloan Kettering Cancer Center | Inhalational therapy for covid-19 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
-
2013
- 2013-08-21 EP EP13783662.3A patent/EP2887960A2/en not_active Withdrawn
- 2013-08-21 JP JP2015527976A patent/JP2015527357A/ja active Pending
- 2013-08-21 US US14/422,706 patent/US20150306058A1/en not_active Abandoned
- 2013-08-21 RU RU2015110027A patent/RU2015110027A/ru not_active Application Discontinuation
- 2013-08-21 BR BR112015003851A patent/BR112015003851A2/pt not_active IP Right Cessation
- 2013-08-21 AU AU2013304627A patent/AU2013304627A1/en not_active Abandoned
- 2013-08-21 CA CA2882684A patent/CA2882684A1/en not_active Abandoned
- 2013-08-21 CN CN201380044476.9A patent/CN104884089A/zh active Pending
- 2013-08-21 KR KR20157004323A patent/KR20150043342A/ko not_active Withdrawn
- 2013-08-21 WO PCT/IB2013/001814 patent/WO2014030049A2/en not_active Ceased
-
2015
- 2015-02-12 IN IN1147DEN2015 patent/IN2015DN01147A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112015003851A2 (pt) | 2017-08-08 |
| JP2015527357A (ja) | 2015-09-17 |
| CA2882684A1 (en) | 2014-02-27 |
| CN104884089A (zh) | 2015-09-02 |
| WO2014030049A2 (en) | 2014-02-27 |
| KR20150043342A (ko) | 2015-04-22 |
| IN2015DN01147A (enExample) | 2015-06-26 |
| EP2887960A2 (en) | 2015-07-01 |
| US20150306058A1 (en) | 2015-10-29 |
| WO2014030049A3 (en) | 2014-04-17 |
| AU2013304627A1 (en) | 2015-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201290171A1 (ru) | Вводимые перорально кортикостероидные композиции | |
| EA201590835A1 (ru) | Составы с низкой дозой панкрелипазы и кишечнорастворимым покрытием | |
| RU2017134443A (ru) | Способ лечения с применением традипитанта | |
| RU2011110765A (ru) | Фармацевтическая композиция энтакапона или его солей пролонгрированного высвобождения | |
| RU2015134581A (ru) | Доноры нитроксила с улучшенным терапевтическим индексом | |
| MX2025003477A (es) | Uso de reboxetina para el tratamiento de narcolepsia | |
| EP4477267A3 (en) | Collagen peptide-based medicament compositions for use in the treatment of ocular diseases, disorders or wounds | |
| RU2020107732A (ru) | Схема дозирования модулятора s1p с немедленным высвобождением | |
| BR112012030641A2 (pt) | métodos e composições para terapia farmacêutica oral | |
| RU2017120184A (ru) | Лекарства для замедления течения болезни паркинсона | |
| RU2010132580A (ru) | Способы и составы для лечения субарахноидального кровоизлияния коронарной и артериальной аневризмы | |
| RU2015109933A (ru) | Композиции, включающие антитело и камостат мезилат (см) | |
| RU2009101026A (ru) | Применение тимозина-альфа-1 для получения лекарственного средства для лечения злокачественной меланомы на iv стадии | |
| RU2013120345A (ru) | Новые способы лечения инфекции, вызванной вирусом гепатита с | |
| BR112023024210A2 (pt) | Comprimido efervescente orodispersível contendo budesonida para uso no tratamento de esofagite eosinofílica | |
| Wang et al. | Effect of gum chewing on bowel function recovery in patients after radical cystectomy with urinary diversion | |
| Pee et al. | Cerebral air embolism: a rare complication following balloon dilation | |
| MY174442A (en) | Treating critically ill patients with intravenous ibuprofen | |
| RU2013148539A (ru) | Алиспоривир для лечения инфекции вируса гепатита с | |
| Chang et al. | Resolution of a vocal fold polyp treated with Chinese herbal medicine: One case report with literature review | |
| Li et al. | Therapy of both surgical and non-surgical related complication of gastric cancer for the elderly | |
| Oppel | Allopathy—a term that diminishes the profession | |
| Suh et al. | Difference in Helicobacter pylori eradication rates in patients with peptic ulcer and non-ulcer dyspepsia | |
| Smith | Intestinal microbiota transplantation: a case of Crohn’s colitis with superimposed Clostridium difficile infection | |
| CN107961358A (zh) | 一种治疗慢性胃炎的中药及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20160822 |